Reviva Ptb Ratio from 2010 to 2024

RVPH Stock  USD 1.14  0.02  1.79%   
Reviva Pharmaceuticals' PTB Ratio is increasing with slightly volatile movements from year to year. PTB Ratio is estimated to finish at 22.50 this year. PTB Ratio is price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on Reviva Pharmaceuticals' equity relative to its net asset value. View All Fundamentals
 
PTB Ratio  
First Reported
2010-12-31
Previous Quarter
21.4315146
Current Value
22.5
Quarterly Volatility
9.2569707
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Reviva Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Reviva Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 156.3 K, Tax Provision of 10 K or Net Interest Income of 523.9 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 22.5. Reviva financial statements analysis is a perfect complement when working with Reviva Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Reviva Pharmaceuticals Correlation against competitors.

Latest Reviva Pharmaceuticals' Ptb Ratio Growth Pattern

Below is the plot of the Ptb Ratio of Reviva Pharmaceuticals Holdings over the last few years. It is price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value. Reviva Pharmaceuticals' PTB Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Reviva Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Ptb Ratio10 Years Trend
Slightly volatile
   Ptb Ratio   
       Timeline  

Reviva Ptb Ratio Regression Statistics

Arithmetic Mean0.85
Geometric Mean5.07
Coefficient Of Variation1,084
Mean Deviation6.87
Median(4.30)
Standard Deviation9.26
Sample Variance85.69
Range26.7954
R-Value0.77
Mean Square Error38.15
R-Squared0.59
Significance0.0009
Slope1.59
Total Sum of Squares1,200

Reviva Ptb Ratio History

2024 22.5
2023 21.43
2022 6.73
2021 1.49
2020 3.6

About Reviva Pharmaceuticals Financial Statements

Investors use fundamental indicators, such as Reviva Pharmaceuticals' Ptb Ratio, to determine how well the company is positioned to perform in the future. Although Reviva Pharmaceuticals' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
PTB Ratio 21.43  22.50 

Currently Active Assets on Macroaxis

When determining whether Reviva Pharmaceuticals is a strong investment it is important to analyze Reviva Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Reviva Pharmaceuticals' future performance. For an informed investment choice regarding Reviva Stock, refer to the following important reports:
Check out the analysis of Reviva Pharmaceuticals Correlation against competitors.
You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Reviva Pharmaceuticals. If investors know Reviva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Reviva Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.08)
Return On Assets
(2.34)
Return On Equity
(17.95)
The market value of Reviva Pharmaceuticals is measured differently than its book value, which is the value of Reviva that is recorded on the company's balance sheet. Investors also form their own opinion of Reviva Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Reviva Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Reviva Pharmaceuticals' market value can be influenced by many factors that don't directly affect Reviva Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Reviva Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Reviva Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Reviva Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.